Honors & Awards


  • Propel Postdoctoral Scholar, Stanford University (2024)
  • Ruth L. Kirschstein National Research Scholarship Award (NRSA) for Individual Predoctoral Fellows, National Cancer Institute, NIH (2022-2024)
  • AACR Minority Scholar in Cancer Research Award, AACR (2022)

Professional Education


  • Doctor of Philosophy, Mount Saint Mary's College (2024)
  • Bachelor of Science, Mount Saint Mary's College (2023)
  • Doctor of Philosophy, Yale University (2024)
  • PhD, Yale University, Genetics (2024)
  • MPhil, Yale University, Genetics (2021)
  • B.S., Mount St. Mary's University, Los Angeles, Biology (2013)

Stanford Advisors


Current Research and Scholarly Interests


Islet biology, diabetes, obesity, pancreatic cancer

Lab Affiliations


All Publications


  • Decoding the obesity-cancer connection: lessons from preclinical models of pancreatic adenocarcinoma. Life science alliance Ruiz, C. F., Garcia, C., Jacox, J. B., Lawres, L., Muzumdar, M. D. 2023; 6 (11)

    Abstract

    Obesity is a metabolic state of energy excess and a risk factor for over a dozen cancer types. Because of the rising worldwide prevalence of obesity, decoding the mechanisms by which obesity promotes tumor initiation and early progression is a societal imperative and could broadly impact human health. Here, we review results from preclinical models that link obesity to cancer, using pancreatic adenocarcinoma as a paradigmatic example. We discuss how obesity drives cancer development by reprogramming the pretumor or tumor cell and its micro- and macro-environments. Specifically, we describe evidence for (1) altered cellular metabolism, (2) hormone dysregulation, (3) inflammation, and (4) microbial dysbiosis in obesity-driven pancreatic tumorigenesis, denoting variables that confound interpretation of these studies, and highlight remaining gaps in knowledge. Recent advances in preclinical modeling and emerging unbiased analytic approaches will aid in further unraveling the complex link between obesity and cancer, informing novel strategies for prevention, interception, and therapy in pancreatic adenocarcinoma and other obesity-associated cancers.

    View details for DOI 10.26508/lsa.202302228

    View details for PubMedID 37648285

    View details for PubMedCentralID PMC10474221

  • Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell Chung, K. M., Singh, J., Lawres, L., Dorans, K. J., Garcia, C., Burkhardt, D. B., Robbins, R., Bhutkar, A., Cardone, R., Zhao, X., Babic, A., Vayrynen, S. A., Dias Costa, A., Nowak, J. A., Chang, D. T., Dunne, R. F., Hezel, A. F., Koong, A. C., Wilhelm, J. J., Bellin, M. D., Nylander, V., Gloyn, A. L., McCarthy, M. I., Kibbey, R. G., Krishnaswamy, S., Wolpin, B. M., Jacks, T., Fuchs, C. S., Muzumdar, M. D. 2020

    Abstract

    Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well understood. Leveraging an autochthonous mouse model, we demonstrate a causal and reversible role for obesity in early PDAC progression, showing that obesity markedly enhances tumorigenesis, while genetic or dietary induction of weight loss intercepts cancer development. Molecular analyses of human and murine samples define microenvironmental consequences of obesity that foster tumorigenesis rather than new driver gene mutations, including significant pancreatic islet cell adaptation in obesity-associated tumors. Specifically, we identify aberrant beta cell expression of the peptide hormone cholecystokinin (Cck) in response to obesity and show that islet Cck promotes oncogenic Kras-driven pancreatic ductal tumorigenesis. Our studies argue that PDAC progression is driven by local obesity-associated changes in the tumor microenvironment and implicate endocrine-exocrine signaling beyond insulin in PDAC development.

    View details for DOI 10.1016/j.cell.2020.03.062

    View details for PubMedID 32304665